Janssen Pharmaceuticals is providing refunds for 340B overcharges on 14 widely used products during the first and second quarters of 2021.

340B REPORT SPONSOR SPOTLIGHT

Janssen Providing Refunds for 340B Overcharges Including Diabetes Drug

Drug manufacturer Janssen, a Johnson & Johnson company, has notified 340B covered entities they are or might be owed refunds for overcharges on 14 widely used products during the first and second quarters of 2021.

Janssen asked the U.S. Health Resources and Services Administration (HRSA) to post the notice dated Sept. 17 on HRSA’s website. The products include eight NDCs for the type 2 diabetes medicine Invokamet, one NDC for the antipsychotic Risperdal, two NDCs for the immunosuppressive drug Simponi, and three NDC for the blood thinner Xarelto.

“Janssen will be communicating with and issuing refund adjustments through the wholesalers that submitted the original sale on behalf of the 340B covered entities,” the notice says. It includes an email address for entities to use “if you feel you have not received an

appropriate adjustment.”

Editor at Large | Website | + posts
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report